This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 May 2011

Oxford Biomedica Inks Antibody Deal with Pfizer

Oxford BioMedica has expanded its 5T4 tumor antigen therapeutics collaboration with Pfizer.

Oxford BioMedica, a UK-based gene therapy company, has expanded its collaboration with Pfizer to develop therapeutic products targeting the company's proprietary 5T4 tumour antigen for the treatment of cancer.


The amended agreement grants Pfizer non-exclusive rights to the diagnostic use of 5T4 antibodies against the antigen and includes an option to commercialise a 5T4-based diagnostic.


Oxford BioMedica could earn up to US$4m in upfront, development and commercial milestone payments, in addition to revenues from further commercialisation.


The original licensing agreement was signed with Wyeth (acquired by Pfizer in 2009) in 2001, and granted global rights to ma

Related News